Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients

Table 4 Treatment related adverse events, n (%)

	TT group (n = 1011)	CT group (n = 972)	P value
Eradication related Side effects			< 0.001
No	78 (77.23)	48 (49.48)
Yes	23 (22.77)	49 (50.52)
Taste disturbance	2 (1.98)	18 (18.56)
Nausea/vomiting	10 (9.90)	15 (15.46)
Diarrhea/loose stool/constipation	6 (5.94)	9 (9.28)
Abdominal discomfort, dyspepsia	3 (2.97)	3 (3.09)
General weakness, myalgia	1 (0.99)	1 (1.03)
Dizziness, headache	1 (0.99)	2 (2.06)
Skin rash	0 (0.00)	1 (1.03)

¹Of the 110 patients who were initially allocated into the tailored therapy (TT) group, 9 were not followed up. Therefore, a total of 101 patients were included in the TT group.

²Of the 107 patients who were initially allocated into the concomitant therapy (CT) group, 10 were lost to follow up. Therefore, a total of 97 patients were included in the CT group, regardless of compliance status. TT: Tailored therapy; CT: Concomitant therapy.